Localized treatment of solid tumors with radiation triggered liposomes

Rejuvenics Technologies正在开发一种专利技术，该技术利用局部电离辐射来触发封装在放射敏感脂质体中的化疗药物的释放。这种首创的方法同时将放射治疗和化疗药物递送靶向实体瘤;最大限度地减少对重要器官的毒性暴露并可能提高疗效。在这个I期计划中，Rejuvenics将与阿肯色州医学科学大学的专家合作，通过三个目标开发封装的化疗辐射触发脂质体（RTL）：1）选择封装在RTL 001中的主要化疗药物，并表征RTL 001的辐射剂量反应; 2）确定RTL 001在小鼠中的生物分布和药代动力学;和3）评估小鼠中RTL 001的局部抗肿瘤功效。这些结果代表了Rejuvenics准备II期研究时对FDA预提交过程至关重要的关键临床前里程碑。我们奋进于证明RTLs能够实现更安全、可控的化疗递送，以治疗非转移性肺癌，克服全身毒性，并改善数百万癌症患者的临床结局。Rejuvenics的癌症，药物开发和放射研究人员和行业专家团队准备成功执行这项研究，为NIH提供切实的结果，并将产品开发推向临床测试，沿着商业化道路前进。

Rejuvenics Technologies is developing a patented technology that utilizes localized ionizing radiation to trigger release of chemotherapeutic agents encapsulated inside radio-sensitive liposomes. This first-of-its- kind methodology simultaneously targets radiotherapy and delivery of chemotherapeutics to solid tumors; minimizing toxic exposure to vital organs and potentially enhancing efficacy. In this Phase I proposal, Rejuvenics will develop encapsulated chemotherapy Radiation-Triggered Liposomes (RTLs), through three Objectives in collaboration with experts at the University of Arkansas for Medical Sciences: 1) Select the lead chemotherapeutic to encapsulate in RTL001 and characterize the radiation dose response of RTL001; 2) Determine biodistribution and pharmacokinetics of RTL001 in mice; and 3) Assess localized anti-tumor efficacy of RTL001 in mice. These results represent key pre-clinical milestones important to the FDA Pre-Submission process as Rejuvenics prepares for Phase II studies. We endeavor to demonstrate the ability of RTLs to achieve safer, controlled delivery of chemotherapy to treat non-metastatic lung cancer, overcome systemic toxicity, and improve clinical outcomes for millions of cancer patients. Rejuvenics' team of cancer, drug development and radiation researchers and industry experts is prepared to successfully execute this study, deliver tangible results to the NIH, and advance the product development toward clinical testing along the path to commercialization.